Slingshot members are tracking this event:

Agios Pharma (AGIO) to report data from Phase 2 study of AG-348 in patients with PK deficiency in at European Hematology Association Meeting

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks


Additional Information

Additional Relevant Details This is a Phase 2, open label, two arm, multicenter, randomized, dose-ranging study during which adult patients with PK deficiency will receive multiple doses of AG-348 for up to 24 weeks. Up to 25 patients will be randomized to two doses of AG-348; a third arm (up to 25 patients) may be added, if required. AG-348 will be administered orally at various doses; if implemented, the dose of Arm 3 will be determined based on ongoing review. Data will be reviewed on a regular basis and study design, dose and schedule will be adapted based on these reviews. The study will evaluate the safety and tolerability of multiple doses of AG-348, pharmacokinetic (PK) and pharmacodynamic (PD) profile of AG-348 and early indicators of clinical efficacy
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jun 11, 2016
Occurred Source:
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Interim Data, Phase 2a Interim Data, Ag-348, Pk Deficiency, European Hematology Association, Pyruvate Kinase Deficiency, Open-label